← Eichor
Study identifier: NCT07587632 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Natural Cervical Ripening to Prevent Pharmacological Induction of Labor - a Pilot Study.

Condition: Pregnancy · Induction of Labor · Gestational Diabetes Mellitus (GDM)  ·  Sponsor: University of Zurich

PhaseNA
Planned participants74
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

As of today, around 25% of all vaginal births happen after induction of labor (IOL). The internal guidelines of the University Hospital Zurich currently recommend pregnant women with a non-insulin dependent gestational diabetes an IOL around term. One possibility to prevent an IOL and increase the chance for a spontaneous onset of birth is a ripening of the cervix by alternative methods in an outpatient setting. The primary objective of this study is to evaluate the effect of natural cervical ripening methods on the time interval between 37 weeks (beginning of the intervention) and the onset of spontaneous labor.

This description comes directly from the study's public registry record.

Talk to the study team

Verena Bossung, PD Dr. med.  ·  +44 43 253 28 47  ·  verena.bossung@usz.ch

Nicole Ochsenbein, Prof. Dr. med  ·  +41 43 255 51 01  ·  Nicole.Ochsenbein@usz.ch

Always discuss trial participation with your own doctor first.

Locations (1)

University Hospital ZurichZurich, Canton of Zurich, SwitzerlandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07587632